Sustained release intraocular implants and methods for treating ocular neuropathies
First Claim
1. A method of reducing intraocular pressure in an eye of a patient, the method comprising the step of placing a biodegradable drug delivery implant in the anterior chamber of the eye of the patient, the implant consisting of 26% by weight timolol maleate in a poly(D,L-lactide) with an inherent viscosity of 0.3 dl/g, wherein said implant is an extruded filament and the total weight of said implant is about 250 μ
- g, and wherein said implant provides a therapeutically effective amount of timolol maleate to the patient for at least about one week.
1 Assignment
0 Petitions
Accused Products
Abstract
Biocompatible intraocular implants include a beta adrenergic receptor antagonist and a polymer associated with the beta adrenergic receptor antagonist to facilitate release of the beta adrenergic receptor antagonist into an eye for an extended period of time. The beta adrenergic receptor antagonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat one or more ocular conditions, such as an ocular neuropathies, for example, various forms of glaucoma.
154 Citations
1 Claim
-
1. A method of reducing intraocular pressure in an eye of a patient, the method comprising the step of placing a biodegradable drug delivery implant in the anterior chamber of the eye of the patient, the implant consisting of 26% by weight timolol maleate in a poly(D,L-lactide) with an inherent viscosity of 0.3 dl/g, wherein said implant is an extruded filament and the total weight of said implant is about 250 μ
- g, and wherein said implant provides a therapeutically effective amount of timolol maleate to the patient for at least about one week.
Specification
-
- Resources
-
Current AssigneeAllergan, Inc. (Canada) (Abbvie Incorporated)
-
Original AssigneeAllergan, Inc. (Canada) (Abbvie Incorporated)
-
InventorsHuang, Glenn T., Nivaggioli, Thierry
-
Primary Examiner(s)PURDY, KYLE A
-
Application NumberUS12/955,630Publication NumberTime in Patent Office1,254 DaysField of SearchNoneUS Class Current424/426CPC Class CodesA61K 31/5377 not condensed and containin...A61K 9/0051 Ocular inserts, ocular impl...A61P 27/02 Ophthalmic agentsA61P 27/06 Antiglaucoma agents or mioticsA61P 43/00 Drugs for specific purposes...
